Latest Blogs

Nov 28, 2023
Dr. Tara Rajendran honors two women who, through their kindness and thoughtful attention, shaped her professional path from an early age.
Nov 20, 2023
"We all need to stay informed and engaged on the topic of AI in order to be the best advocates for ourselves, our profession, and our patients."
Nov 03, 2023
Millions of people have been affected by the war in Sudan, and the outlook for patients with cancer is particularly dire. Dr. Nabeeha Karadawi, Dr. Salma Awad Elkareem Ali Mohamed, and Nagham Ali outline the current situation and call for immediate international aid.
Oct 24, 2023
If we believe that dietary supplements are active compounds—and many are—then we should deal with them as medications and advise our patients accordingly.
Subscribe to this column

Gilberto Lopes, MD, FASCO, MBA

Gilberto de Lima Lopes Jr., MD, MBA, FAMS, is associate director for global oncology and interim chief for the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center and professor of clinical medicine at the University of Miami in Florida. He returned to the United States after 10 years in Asia and Latin America and has dedicated much of his time to the issues of cancer control and access to medications in low- and middle-income countries. Dr. Lopes is the editor-in-chief for JCO Global Oncology, among other volunteer roles at ASCO. Follow him on Twitter @GlopesMd.

Disclosure.

Jul 26, 2017
My coauthors and I identify deficiencies in prevention and screening efforts that could be acted upon to further reduce cervical cancer incidence and mortality in Latin America.
Mar 20, 2017
When the basics of cancer control are not in place, should we discuss targeted agents and immunotherapy in resource-constrained settings?
Oct 31, 2016
Hope springs eternal in the Brazilian economy and health care system, with cautious optimism for gains in oncology care.
Oct 04, 2016
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Aug 01, 2016
The region has seen structural reforms in health care systems, better training of cancer professionals, new initiatives for populations at high risk, expansion of cancer registries and cancer plans, and implementation of policies to improve prevention, early diagnosis, and treatment.
Jul 11, 2016
Follow-on biologics are here to stay, and represent enormous potential for patients with cancer being treated in low- and middle-income countries.

Pages